Evaluation of the Survival Outcomes of Multiple Myeloma Patients According to Their Plasmacytoma Presentation at Diagnosis

Creative Commons License

Ciftciler R., GÖKER H., DEMİROĞLU H., AKSU S., SAYINALP N., HAZNEDAROĞLU İ. C., ...Daha Fazla

TURKISH JOURNAL OF HEMATOLOGY, cilt.37, sa.4, ss.256-262, 2020 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 37 Sayı: 4
  • Basım Tarihi: 2020
  • Doi Numarası: 10.4274/tjh.galenos.2019.2019.0061
  • Dergi Adı: TURKISH JOURNAL OF HEMATOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CINAHL, EMBASE, MEDLINE, Directory of Open Access Journals, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.256-262
  • Anahtar Kelimeler: Multiple myeloma, Bone-related plasmacytoma, Soft tissue-related plasmacytoma, EXTRAMEDULLARY DISEASE, PRESENTING FEATURES, THALIDOMIDE, BORTEZOMIB, CRITERIA, IMPACT
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Objective: Multiple myeloma (MM) associated with extramedullary (EM) plasmacytoma has a poor therapeutic response and poor outcomes when treated with conventional chemotherapy. EM plasmacytoma is divided into two groups: the first group comprises tumors that are extending directly from osteolytic bone lesions (EM-B, bone-related), while the second results from plasmacytoma infiltration into soft tissues with no relationship to the bone (EM-S, soft tissuerelated). This study aimed to compare the general characteristics and survival outcomes of transplant-eligible MM patients who had EM-S or EM-B and MM patients who did not have plasmacytoma at the time of diagnosis.